Celsion still on track to take PhIII ThermoDox trial to final analysis at year end
This article was originally published in Scrip
Executive Summary
Celsion will be continuing the multinational Phase III HEAT study investigating its heat-activated doxorubicin product, ThermoDox, in primary liver cancer, to its final analysis at the end of the year. The company had hoped that a positive interim analysis of the trial would have led to an early end to the trial, but the independent data monitoring committee (DMC) unanimously recommended continuation.